Ethical restrictions from the Regional Ethics Committee in Stockholm require that the data be kept at the Department of Communicable Disease and Prevention in Stockholm (2013/1728-31/1). However, in cases of scientific inquiry, data can be made accessible upon request. Requests for the data are to be made directly to the Department of Communicable Disease Control and Prevention (Smittskydd Stockholm), attention Åke Örtqvist, MD Phd, County Medical Officer.

Introduction {#sec001}
============

Gonorrhoea incidence has increased substantially in Stockholm during the past years \[[@pone.0155017.ref001]\] "[Fig 1](#pone.0155017.g001){ref-type="fig"}". The advent of Nucleic Acid Amplification Tests (NAAT) for *Neisseria gonorrhoeae* has led to a higher prevalence of gonorrhoea testing in the population with well over 100 000 tests annually, 70% of those among women. Due to ease of use and high test performance, NAATs could feasibly increase diagnostic yield, thereby helping control the spread of gonorrhoea. Before the introduction of NAAT in 2010, approximately 25 000 tests (cultures) were performed annually in the Stockholm region. NAATs are taken at a wide variety of primary care and outpatient clinics throughout the region. When positive, culture specimens are requested from specific clinics for sexually transmitted infections (STI) as Stockholm has a system of centralized referrals for gonorrhoea confirmation, treatment and contract tracing.

![Trends in gonorrhoea, Stockholm region 2000--201.](pone.0155017.g001){#pone.0155017.g001}

Among heterosexual women in Sweden, the number of reported cases increased by approximately 150% after the introduction of NAAT \[[@pone.0155017.ref002]\]. Increases in both heterosexual men and men having sex with men (MSM) have been 35%. In Sweden, the Communicable Diseases Act from 2004 states that gonorrhoea diagnosis entails mandatory reporting to communicable disease authorities with subsequent contact tracing required. Contract tracing requires individuals to name all sexual contacts potentially involved, thus the personal and social consequences of a diagnosis could be significant. Before treatment is initiated, it is recommended that antibiotic sensitivity of the isolate be determined using culture-based methods \[[@pone.0155017.ref003]\]. This is done in order to avoid ineffective treatments with inherent risks for patient sequelae and on a broader scale to prevent development and spread of multi-resistant bacteria.

However, a substantial portion of cases positive with NAAT cannot be verified by culture and hence it is not possible to determine resistance patterns. If these cases are treated, they often receive a standard treatment that may not be effective and potentially lead to an increase in antibiotic resistance \[[@pone.0155017.ref004]\]. In some countries, see and treat strategies are used due to fears that patients will not return for treatment if test positive \[[@pone.0155017.ref005]\]. If resistance patterns could be identified using molecular techniques the problem with inappropriate treatment would be more easily solved \[[@pone.0155017.ref006],[@pone.0155017.ref007]\].

Uncertainty in diagnostics and treatment of NAAT positive, culture negative gonorrhoea can lead not only to physical complications but also to psycho-social complications and distress for those diagnosed. In this emerging field of NAAT-based testing for gonorrhoea, more knowledge is needed on epidemiological risk factors for testing result discordance so as to best inform public health practices optimal for individual infection care. Therefore, the objective of this study is to examine various epidemiological risk factors for NAAT positive but culture negative gonorrhoea cases to better understand these increasing incidence rate trends and result discordance.

Materials and Methods {#sec002}
=====================

Cohort {#sec003}
------

Data were obtained from Sweden's national electronic surveillance system for the reporting of communicable diseases, SmiNet, where all gonorrhoea cases and suspected cases are reported. According to the National Board of Health and Welfare in 2008, cases of gonorrhoea were defined by the following criteria; 1) *N*. *gonorrhoeae* culture positive from a clinical sample or 2) *N*. *gonorrhoeae* NAAT positive in clinical a sample or 3) findings of Gram-negative intracellular diplococci from urethra smear from men \[[@pone.0155017.ref008]\]. As of 2012, *N*. *gonorrhoeae* NAAT positive in clinical sample had to be confirmed with a positive culture according to the guidelines from the National Board of Health and Welfare \[[@pone.0155017.ref009]\]. However, this confirmation requirement was not consistently followed. Every NAAT positive test was still reported to SmiNet regardless of the culture result. During the study period, January 1, 2011-December 31, 2012, 1236 cases of gonorrhoea were reported in Stockholm County. Cases were excluded (n = 362) if a) no NAAT (n = 332), b) no culture n = (9), c) antibiotic treatment after NAAT but before culture(n = 7) or d) NAAT from rectum, throat or eye, as the method was not approved by ISO-certification (n = 14). In total, 874 cases having at least one positive *N*. *gonorrhoeae* NAAT test and follow-up cultures were included. Data on sex, age, mode of transmission, NAAT-test location, symptoms, Chlamydia trachomatis co-infection two months prior to or after gonorrhoea diagnosis, reason for testing, culture location, days between NAAT and culture, and NAAT method were collected from clinical and laboratory data. Three different NAAT methods were in use in the county of Stockholm. The majority of samples were analysed by the Becton Dickinson technique using SDA, which is an isothermal technology utilized to generate billions of copies of target molecules from a single DNA template. The other methods are Roche Cobas 4800 utilizing amplification of target DNA by the Polymerase Chain Reaction (PCR) followed by nucleic acid hybridization, and the Abbott RealTime which is a polymerase chain reaction (PCR) assay for the direct, qualitative detection of the genomic DNA of *N*. *gonorrhoeae*. All three Stockholm laboratories report positive tests (NAATs and/or cultures) in SmiNet. Positive NAAT were not confirmed with second NAAT primers during the study period.

Clinicians are required to report data on mode of transmission (hetero or homosexual), presence of symptoms (yes/no) and reason for gonorrhoea testing (contact tracing, belonging to a high risk group or symptoms) into SmiNet. The definition of which individuals are considered as part of a 'high risk group' is not predefined and is up to reporting clinicians to define. Gonorrhoea cases are defined by reported clinical and laboratory data.

Analyses {#sec004}
--------

Descriptive statistics, including annual incidence trends per 100 000 were performed, stratified by sex. Main outcome variable is defined as a positive NAAT but negative follow-up culture (+-) and will hereafter be referred to as discordant cases. Univariate and multivariate logistic regression were performed where exposure covariates most likely to affect outcome were included in the univariate and multivariate models. Odds-ratios with ninety-five percent confidence intervals were assessed in the model building process. Multicollinearity was evaluated prior to constructing final models. As the variables "symptoms" and "reason for gonorrhoea testing" were collinear, only one of these variables was used in each of the final models. Three separate models were used for combined and sex stratified analyses: 1) univariate, 2) multivariate using the variable "symptoms" and excluding "reason for testing" and 3) multivariate using the variable "reason for testing" and excluding the variable "symptoms". SAS Enterprise Guide version 5.1 was used for data management and analysis.

This study was granted ethical approval by the Regional Ethics Committee in Stockholm (Dnr 2013/1728-31/1-2013) for the use of routinely collected surveillance data. Surveillance routines for this specific disease area dictate that all records be collected without the use of a unique identifier. Prior to the analysis, steps were taken to further remove all possible personal identifiers and only anonymized and de-identified data were used in the analysis. No informed consent for these de-identified data was required by the ethical approval committee.

Results {#sec005}
=======

In total, 874 individuals were included in the study, 501 men and 373 women. Thirty-three percent of NAAT positive cases tested negative in the culture based method (n = 289) ([Table 1](#pone.0155017.t001){ref-type="table"}). Fifty-one percent of the women with positive NAAT were discordant cases, while the corresponding number for men was 20%. Mean age was 24 for women and 31 for men. Individuals in the oldest age group had a lower proportion of discordant cases compared to the other age groups. No differences in discordant cases were seen between individuals with and without chlamydia co-infection. Among those who were symptomatic at testing, 22% were discordant cases. For those without symptoms the corresponding number was 51%. Individuals whose reason for testing was due to contract tracing had a higher proportion of discordant results (44%) compared to those tested due to symptoms (23%) or because they belonged to a risk group Abbot Real Time and Roche Cobas 4800 had results with lower discordance (24% and 23% respectively) compared to Becton Dickinson SDA (36%). Mean days between NAAT and culture were 7.5 for discordant cases and 3.5 for culture-positive. No differences in discordant cases were seen among heterosexual vs. homosexual transmission (17% respectively).

10.1371/journal.pone.0155017.t001

###### Descriptive information on gonorrhea NAAT positive cases included in the study. 2011--2012.

![](pone.0155017.t001){#pone.0155017.t001g}

                                                                               Culture neg n (%)[^a^](#t001fn001){ref-type="table-fn"}   Culture pos n (%)[^a^](#t001fn001){ref-type="table-fn"}   Total
  ---------------------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------- -------
  **Total**                                                                    289                                                       585                                                       874
  **Sex**                                                                                                                                                                                          
  Men                                                                          98 (20%)                                                  403 (80%)                                                 501
  Women                                                                        191 (51%)                                                 182 (49%)                                                 373
  **Age group**                                                                                                                                                                                    
  \< 20 yrs                                                                    54 (39%)                                                  86(61%)                                                   140
  20--29 yrs                                                                   151(35%)                                                  287 (65%)                                                 429
  30--39 yrs                                                                   53 (32%)                                                  113 (68%)                                                 166
  40- yrs                                                                      31 (22%)                                                  108 (78%)                                                 139
  **Chlamydia co-infection**                                                                                                                                                                       
  Yes                                                                          41 (30%)                                                  95 (70%)                                                  136
  No                                                                           248 (34%)                                                 490 (66%)                                                 738
  **Symptoms**                                                                                                                                                                                     
  Yes                                                                          131 (22%)                                                 456 (78%)                                                 587
  No                                                                           123 (51%)                                                 120 (49%)                                                 243
  Missing                                                                      35 (80%)                                                  9 (20%)                                                   44
  **Reason for testing**                                                                                                                                                                           
  Symptoms                                                                     117 (23%)                                                 381 (77%)                                                 498
  Contact tracing                                                              68 (44%)                                                  86 (56%)                                                  154
  Risk group                                                                   33 (24%)                                                  102 (76%)                                                 135
  **NAAT method**                                                                                                                                                                                  
  Becton Dickinson SDA                                                         248 (36%)                                                 449 (64%)                                                 697
  Abbott Real Time                                                             16 (24%)                                                  51 (76%)                                                  67
  Roche Cobas 4800                                                             25 (23%)                                                  83 (77%)                                                  108
  Missing                                                                      0                                                         2 (100%)                                                  2
  **Days between NAAT and culture**                                                                                                                                                                
  \< 7 days                                                                    108 (20%)                                                 444 (80%)                                                 552
  7- days                                                                      103 (42%)                                                 141 (58%)                                                 244
  Missing                                                                      78 (100%)                                                                                                           78
  **Mode of transmission (among men)**[^b^](#t001fn002){ref-type="table-fn"}                                                                                                                       
  Homosexual transmission                                                      36 (17%)                                                  182 (83%)                                                 218
  Heterosexual transmission                                                    45 (17%)                                                  214 (83%)                                                 259
  Missing/other                                                                17 (71%)                                                  7 (29%)                                                   24

^a^ Row percent shown

^b^ Among women there was no homosexual transmission reported

Women were four-times more likely than men to be discordant (OR 4.0; 95% CI 2.4--6.7) ([Table 2](#pone.0155017.t002){ref-type="table"}, model 1). Individuals tested for gonorrhoea without symptoms were 2.3 times more likely than those with symptoms to be discordant (95% CI 1.5--3.5). NAAT methods Abbot Real Time (OR 0.4: 95% CI .2--0.9) and Roche Cobas 4800 (OR 0.3; 95% CI 0.1--0.5) were associated with a decreased risk of discordancy compared to Becton Dickinson SDA. One week or more between NAAT and culture testing was also indicative of an increased likelihood for discordant results. When adjusting for the variable "reason for testing" instead of the variable "symptoms", differences between men and women increased substantially, indicating effect modification by sex and warranting a stratified model.

10.1371/journal.pone.0155017.t002

###### Multivariate logistic regression modeling risks for gonorrhea NAAT positive, culture negative cases, presented as odds ratios with 95% confidence intervals.
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                                            OR[^a^](#t002fn001){ref-type="table-fn"}   (95% CI)     OR[^b^](#t002fn002){ref-type="table-fn"}   (95% CI)     OR[^c^](#t002fn003){ref-type="table-fn"}   (95% CI)
  ----------------------------------- ----- ------------------------------------------ ------------ ------------------------------------------ ------------ ------------------------------------------ ------------
  **Sex**                                                                                                                                                                                              
  Men                                 98    ref                                                     ref                                                                                                
  Women                               191   4.3                                        (3.2--5.8)   4.0                                        (2.4--6.7)   5.3                                        (3.1--9.2)
  **Age group**                                                                                                                                                                                        
  \< 20 yrs                           54    ref                                                     ref                                                                                                
  20--29 yrs                          151   0.9                                        (0.6--1.3)   1.6                                        (1.0--2.7)   1.8                                        (1.0--3.3)
  30--39 yrs                          53    0.7                                        (0.5--1.2)   1.8                                        (0.9--3.6)   1.8                                        (0.8--3.7)
  40- yrs                             31    0.5                                        (0.3--0.8)   1.6                                        (0.8--3.4)   1.6                                        (0.7--3.4)
  **Chlamydia co-infection**                                                                                                                                                                           
  No                                  248   ref                                                     ref                                                                                                
  Yes                                 41    0.9                                        (0.6--1.3)   0.8                                        (0.5--1.4)   0.8                                        (0.5--1.4)
  **Symptoms**                                                                                                                                                                                         
  Yes                                 131   ref                                                     ref                                                                                                
  No                                  123   3.6                                        (2.6--4.9)   2.3                                        (1.5--3.5)                                              
  **Reason for testing**                                                                                                                                                                               
  Symptoms                            117   Ref                                                                                                                                                        
  Contact tracing                     68    2.6                                                                                                             2.5                                        (1.6--2.7)
  Risk group                          35    1.1                                                                                                             0.8                                        (0.4--1.3)
  **NAAT method**                                                                                                                                                                                      
  Becton Dickinson SDA                248   ref                                                     ref                                                                                                
  Abbott Real Time                    16    0.6                                        (0.3--1.0)   0.4                                        (0.2--0.9)   0.4                                        (0.2--1.0)
  Roche Cobas 4800                    25    0.5                                        (0.3--0.9)   0.3                                        (0.1--0.5)   0.3                                        (0.1--0.6)
  **Days between NAAT and culture**                                                                                                                                                                    
  \< 7 days                           108   ref                                                     ref                                                                                                
  7- days                             103   3.0                                        (2.2--4.2)   2.6                                        (1.7--4.0)   2.5                                        (1.6--3.9)
  **Mode of transmission**                                                                                                                                                                             
  Heterosexual transmission           45    ref                                                     ref                                                                                                
  Homosexual transmission             36    0.4                                        (0.2--0.5)   1.1                                        (0.6--2.7)   1.6                                        (0.8--2.9)

^a^ Univariate model

^b^ Multivariate model including, sex, age group, chlamydia co-infection, symptoms, NAAT method, days between NAAT and culture and mode of transmission

^c^ Multivariate model including, sex, age group, chlamydia co-infection, reason for testing, NAAT method, days between NAAT and culture and mode of transmission

When stratifying analyses based on sex, men without symptoms had significantly increased risk for discordant results (OR 6.6; 95% CI 3.3--13.3) while symptoms were not predictive for women (OR 1.4; 95% CI 0.8--2.2) ([Table 3](#pone.0155017.t003){ref-type="table"}). In contrast, there was decreased risk for women being discordant when contact tracing (as opposed to symptoms) was the reason for testing (OR 0.4; 95% CI 0.2--0.8). This effect was not seen among men (OR 2.1 95% CI 0.9--5.1). One week or more between NAAT and culture testing were indicative of an increased likelihood for discordant results among men (OR 6.3; 95% CI 3.0--13.1) but less so among women (OR 1.7; 95% CI 1.0--2.8).

10.1371/journal.pone.0155017.t003

###### Stratified multivariate analyses modeling risks for gonorrhea NAAT positive, culture negative cases, presented as odds ratios with 95% confidence intervals.
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                                                                  WOMEN   MEN                                                                                          
  --------------------------------------------------------------- ------- ---------------- ---------------- ----------------- ---- ----------------- ----------------- -----------------
  **Age group**                                                                                                                                                        
  \< 20 yrs                                                       49      ref              ref              ref               5    ref               ref               ref
  20--29 yrs                                                      109     1.5 (1.0--2.4)   1.6 (0.9--2.8)   2.3 (1.1--3.7)    42   1.1 (0.4--3.1)    1.8 (0.3--9.2)    1.7 (0.3--8.6)
  30--39 yrs                                                      23      1.8 (0.9--3.8)   1.7 (0.7--4.0)   1.5 (1.5--4.3)    30   1.5 (0.5--4.2)    2.4 (0.4--13.4)   2.0 (0.4--10.9)
  40- yrs                                                         10      0.9 (0.4--2.2)   0.6 (0.2--1.9)   0.8 (0.2--2.8)    21   1.1 (0.4--3.1)    3.1 (0.6--17.4)   2.5 (0.5--13.3)
  **Chlamydia co-infection**                                                                                                                                           
  No                                                              165     ref              ref              ref               83   ref               ref               ref
  Yes                                                             26      0.6 (0.4--1.1)   0.7 (0.3--1.3)   0.8 (0.4--1.65)   15   1.1 (0.6--2.0)    1.0 (0.4--2.3)    0.8 (0.3--1.9)
  **Symptoms**                                                                                                                                                         
  Yes                                                             82      ref              ref                                49   ref               ref               
  No                                                              87      1.4 (0.9--2.1)   1.4 (0.8--2.2)                     36   6.1 (3.6--10.4)   6.6 (3.3--13.3)   
  **Reason for testing**                                                                                                                                               
  Symptoms                                                        72      ref                               ref               45   ref                                 ref
  Contact tracing                                                 20      0.4 (0.2--0.7)                    0.4 (0.2--0.8)    13   1.9 (1.0--3.9)                      2.1 (0.9--5.1)
  Risk group                                                      48      1.2 (0.7--2.0)                    1.2 (0.6--2.2)    20   3.1 (1.7--5.7)                      3.0 (1.3--6.6)
  **NAAT method**                                                                                                                                                      
  Becton Dickinson SDA                                            161     ref              ref              ref               87   ref               ref               ref
  Roche Cobas 4800                                                17      0.3 (0.2--0.5)   0.2(0.1--0.4)    0.2(0.1--0.5)     8    0.3 (0.1--1.1)    0.7 (0.2--2.3)    0.7 (0.2--2.2)
  Abbott Real Time                                                13      0.5 (0.3--1.1)   0.5 (0.2--1.2)   0.5 (0.2--1.4)    3    0.8 (0.4--1.7)    0.3 (0.1--1.5)    0.2 (0.02--1.7)
  **Days between NAAT and culture**                                                                                                                                    
  \< 7 days                                                       63      ref              ref              ref               45   ref               ref               ref
  7- days                                                         78      1.3 (0.9--2.1)   1.7 (1.0--2.8)   1.5 (0.9--2.6)    25   3.7 (2.1--6.5)    6.3 (3.0--13.1)   5.9 (2.8--12.3)
  **Mode of transmission**[\*](#t003fn005){ref-type="table-fn"}                                                                                                        
  Heterosexual transmission                                                                                                   45   ref               ref               ref
  Homosexual transmission                                                                                                     36   0.9 (0.6--1.5)    1.2 (0.6--2.6)    1.9 (0.9--3.9)

^a^ Number of cases

^b^Univariate model

^c^ Multivariate model including, sex, age group, chlamydia co-infection, symptoms, NAAT method, days between NAAT and culture and mode of transmission

^d^ Multivariate model including, sex, age group, chlamydia co-infection, reason for testing, NAAT method, days between NAAT and culture and mode of transmission

\* Among women there were no homosexual transmission reported

Discussion {#sec006}
==========

This is the first study that examines epidemiological risk factors among gonorrhoea cases for culture negative confirmation after positive NAAT. The increased testing with NAAT has given rise to uncertainty in gonorrhoea diagnostics and risk for incorrect treatment among culture negative cases. Women are four times more likely than men to have discordant results. Men with symptoms were more likely to have culture positive confirmation tests. However for women, symptoms were not related to positive confirmations. Women were most likely to have conclusive results when they were tested due to contact tracing, a finding not true for men. These pronounced sex and symptom based differences warrant a review of testing practices.

Biological factors may account for some of these sex differences. *N*. *gonorrhoeae* is one member of the genus Neisseria. Other Neisseria species (*N*. *lactamica* or *N*. *subflava* for example) can exist in vaginal normal flora and are not pathogenic but can cross-react with *N*. *gonorrhoeae*, thereby lowering NAAT specificity for women depending on circulating genus-types in the population tested \[[@pone.0155017.ref010],[@pone.0155017.ref011]\]. The BD Probe Tech, used as one of three Stockholm laboratory methods shows increased risk for cross reaction with *N*. *lactamica* \[[@pone.0155017.ref011]\].Tests analysed with BD Probe Tech had an increased risk for culture-negative results in our study which could corroborate this cross-reaction risk. Our study excluded tests from non-genital locations as NAAT are location-sensitive and if taken from the oropharynx for example, positive results potentially reflect a cross-reaction \[[@pone.0155017.ref011]\].

Between 90--95% of men contracting gonorrhoea develop genital symptoms of which the most common is urethritis, dysuria and/or purulent discharge within a week after exposure \[[@pone.0155017.ref012],[@pone.0155017.ref013]\]. Men discovering discharge are more likely to seek medical help, whereas women having daily discharge would be less observant to subtle changes. This is clearly substantiated by our study which shows asymptomatic men are six-times more likely to have discordant results. For women, genital symptoms such as dysuria and cervicitis are indicative of various STIs or lower urinary tract infections \[[@pone.0155017.ref012],[@pone.0155017.ref013]\]. However, over 50% with gonococcal cervicitis are entirely asymptomatic \[[@pone.0155017.ref013]\]. This would explain why symptoms among women were not associated with culture-positive results in our study. As with other bacteria, could it be that individuals without symptoms but with positive NAAT are merely transient carriers of gonorrhoea DNA and therefore have negative culture results? Or could it be that some individuals actually clear the infection but may have enough gonococcal DNA for a positive NAAT test? Our study has brought these questions to our attention but it was not possible for us to address them with available data.

Neisseria are fastidious bacteria and the time from testing to laboratory processing is crucial. Viability drops rapidly within hours after sampling and prompt transportation and proper storage is recommended \[[@pone.0155017.ref014]\]. One study on transport revealed only 67% of the positive NAATs (BD Probe Tec) was confirmed by culture \[[@pone.0155017.ref014]\]. Transport time between Stockholm clinics and laboratories is minimal (\<24 hours) due to well-established routines. We were not able to specifically measure transport time but we have no reason to believe that transport time varies between culture-negative and culture-positive cases.

Concerns have been voiced about a high proportion of false positives for gonorrhoea NAAT screening, especially in a low prevalence population \[[@pone.0155017.ref006],[@pone.0155017.ref015],[@pone.0155017.ref016]\]. The relationship between specificity, disease prevalence and positive predictive value, makes it important to take positive predictive value into account prior to wide-spread testing. The estimated prevalence for gonorrhoea in the general population is less than 1%, with the estimated prevalence rising to 15--35% among high risk groups such as MSM \[[@pone.0155017.ref010],[@pone.0155017.ref017],[@pone.0155017.ref018]\]. Men tested in our study were more likely part of a high risk group, compared to women.

In one report positive predictive value was calculated to be only 77% assuming a test specificity of 99.7% in a population with a prevalence of 1% \[[@pone.0155017.ref019]\]. CDC and Public Health England only recommend screening for a gonorrhoea infection if the positive predictive value is greater or equal to 90% \[[@pone.0155017.ref020]\]. One study suggests a high cut-off value for NAAT, as low level positive results need to be interpreted with caution because, in that study, none of the low level results were confirmed with culture or confirmatory NAAT \[[@pone.0155017.ref015]\]. In our study, there were considerably more women than men being tested during the study period (87 228 women and 41896 men). When first introduced, the gonorrhoea NAAT was co-analyzed with the existing chlamydia test. These tests were routinely offered those visiting youth clinics, the vast majority of visitors being women. When testing women without specified indications, the risk of low positive predictive value increases.

The use of a second NAAT with different DNA targets is recommended to verify a positive NAAT for gonorrhoea \[[@pone.0155017.ref021]\]. This is estimated to increase the positive predictive value to near 100% \[[@pone.0155017.ref019]\]. Dual NAAT or confirmatory testing is not yet standard practice in this emerging testing field, partly due to feasibility and costs \[[@pone.0155017.ref010],[@pone.0155017.ref022]\]. However, this routine is now implemented by the microbiological laboratories in the Stockholm region. This, in addition to specified indications for screening in the population, would increase the positive predictive value.

The study has several limitations. There is no clear definition for the terms 'risk group' or 'symptoms' in SmiNet. Individual clinicians may define those terms differently between men and women. Sample locations also differ between men and women. Therefore, stratifying by sex will account for any misclassification of exposure or differences in culture sample location. Our study includes different population groups including women and men below 23 years of age attending a youth clinic, those attending sexual health clinics, men who have sex with men attending specialized out-patient clinics, and patients seeing their local GP. However, culture samples are exclusively taken at sexual health and MSM clinics, which limit discrepancies in test routines including transportation.

This study shows that women tested for reasons other than contact tracing, and men tested without symptoms, have substantially increased risks for test method discrepancies. This puts these individuals at jeopardy for indeterminate diagnosis and/or improper treatment of gonorrhoea as well as unnecessary contact tracing. The use of NAATs should be based on proper clinical and epidemiological indications, such as symptoms, contact tracing, sex in countries with higher incidence of gonorrhoea and men having sex with men. Positive NAAT should be followed by a culture-based test, preferably within one week. Confirmation tests, using second NAAT primers is recommended, especially in low prevalence population groups.
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